Ter‐cell, A New Target for Hepatocellular Carcinoma Therapy. (12th October 2018)

• Record Type: Journal Article
• Authors: Cen, Xiaohong; Cheng, Kui
• Is Part Of: Chembiochem. Volume 19:Number 21(2018)
• Page Start: 2254
• Page End: 2256
• Publication Date: 2018-10-12
• Subjects: antitumor agents -- artemin -- cancer -- hepatocellular carcinoma -- therapeutic targets; Biochemistry -- Periodicals; Molecular biology -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1002/cbic.201800410
• Languages: English
• ISSNs: 1439-4227

Abstract

Abstract: Hepatocellular carcinoma (HCC), a malignancy of the liver, has become the second most lethal cause of cancer death globally. Recently, scientists discovered that a splenic erythroblast‐like cell induced by the primary tumor, termed Ter‐cell, promoted HCC progression and metastasis. These findings shed light on the inhibition of Ter‐cell or artemin that can serve as a new therapeutic target for HCC. Abstract : A hard cell : It was recently discovered that a splenic erythroblast‐like cell induced by the primary tumor, termed Ter‐cell, promoted the progression and metastasis of hepatocellular carcinoma (HCC), a malignancy of the liver. Resection of the spleen and the HCC mass or inhibitors of Ter‐cell and artemin could serve as supplementary therapies and therapeutic targets for HCC.